REFERENCES

1. WHO. WHO mortality database. Available from: http://www.who.int/healthinfo/mortality_data/en/. [Last accessed on 7 Jan 2019].

2. White DL, Thrift AP, Kanwal F, Davila J, El-Serag HB. Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012. Gastroenterology 2017;152:812-20.

3. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.

4. Singal AG, Yopp AC, Gupta S, Skinner CS, Halm EA, et al. Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res (Phila) 2012;5:1124-30.

5. Trevisani F, De Notariis S, Rapaccini G, Farinati F, Benvegnù L, et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002;97:734-44.

6. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002;35:519-24.

7. Jarnagin W, Chapman WC, Curley S, D’Angelica M, Rosen C, et al. Surgical treatment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford) 2010;12:302-10.

8. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res 2007;37:S88-94.

9. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9.

10. Benson AB 3rd, D’Angelica MI, Abbott DE, Abrams TA, Alberts SR, et al. NCCN guidelines insights: hepatobiliary cancers, version 1.2017. J Natl Compr Canc Netw 2017;15:563-73.

11. Kothary N, Dieterich S, Louie JD, Chang DT, Hofmann LV, et al. Percutaneous implantation of fiducial markers for imaging-guided radiation therapy. AJR Am J Roentgenol 2009;192:1090-6.

12. Kishan AU, Cao M, Mikaeilian AG, Low DA, Kupelian PA, et al. Dosimetric feasibility of magnetic resonance imaging-guided tri-cobalt 60 preoperative intensity modulated radiation therapy for soft tissue sarcomas of the extremity. Pract Radiat Oncol 2015;5:350-6.

13. Eccles CL, Dawson LA, Moseley JL, Brock KK. Interfraction liver shape variability and impact on GTV position during liver stereotactic radiotherapy using abdominal compression. Int J Radiat Oncol Biol Phys 2011;80:938-46.

14. Ten Haken RK, Balter JM, Marsh LH, Robertson JM, Lawrence TS. Potential benefits of eliminating planning target volume expansions for patient breathing in the treatment of liver tumors. Int J Radiat Oncol Biol Phys 1997;38:613-7.

15. Wagman R, Yorke E, Ford E, Giraud P, Mageras G, et al. Respiratory gating for liver tumors: use in dose escalation. Int J Radiat Oncol Biol Phys 2003;55:659-68.

16. Dawson LA, Brock KK, Kazanjian S, Fitch D, McGinn CJ, et al. The reproducibility of organ position using active breathing control (ABC) during liver radiotherapy. Int J Radiat Oncol Biol Phys 2001;51:1410-21.

17. Law AL, Ng WT, Lee MC, Chan AT, Fung KH, et al. Treatment of primary liver cancer using highly-conformal radiotherapy with kV-image guidance and respiratory control. Radiother Oncol 2012;102:56-61.

18. Winter JD, Wong R, Swaminath A, Chow T. Accuracy of robotic radiosurgical liver treatment throughout the respiratory cycle. Int J Radiat Oncol Biol Phys 2015;93:916-24.

19. Wojcieszynski AP, Rosenberg SA, Brower JV, Hullett CR, Geurts MW, et al. Gadoxetate for direct tumor therapy and tracking with real-time MRI-guided stereotactic body radiation therapy of the liver. Radiother Oncol 2016;118:416-8.

20. Hong TS, DeLaney TF, Mamon HJ, Willett CG, Yeap BY, et al. A prospective feasibility study of respiratory-gated proton beam therapy for liver tumors. Pract Radiat Oncol 2014;4:316-22.

21. Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, et al. Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2016;34:460-8.

22. Gandhi SJ, Liang X, Ding X, Zhu TC, Ben-Josef E, et al. Clinical decision tool for optimal delivery of liver stereotactic body radiation therapy: photons versus protons. Pract Radiat Oncol 2015;5:209-18.

23. Tao R, Krishnan S, Bhosale PR, Javle MM, Aloia TA, et al. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysis. J Clin Oncol 2016;34:219-26.

24. Fode MM, Høyer M. Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases. Radiother Oncol 2015;114:155-60.

25. Chen X, Liu L, Pan X. Portal vein tumor thrombus in advanced hepatocellular carcinoma: a case report. Oncol Lett 2015;9:2495-8.

26. Xi M, Zhang L, Zhao L, Li QQ, Guo SP, et al. Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosis. PLoS One 2013;8:e63864.

27. O’Connor JK, Trotter J, Davis GL, Dempster J, Klintmalm GB, et al. Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation. Liver Transpl 2012;18:949-54.

28. Andolino DL, Johnson CS, Maluccio M, Kwo P, Tector AJ, et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2011;81:e447-53.

29. Organ LW. Electrophysiologic principles of radiofrequency lesion making. Appl Neurophysiol 1976- 1977;39:69-76.

30. Eisele RM. Advances in local ablation of malignant liver lesions. World J Gastroenterol 2016;22:3885-91.

31. Llovet JM, Real MI, Montaña X, Planas R, Coll S, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-9.

32. Lencioni R, Petruzzi P, Crocetti L. Chemoembolization of hepatocellular carcinoma. Semin Intervent Radiol 2013;30:3-11.

33. Sapisochin G, Barry A, Doherty M, Fischer S, Goldaracena N, et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol 2017;67:92-9.

34. Su TS, Liang P, Liang J, Lu HZ, Jiang HY, et al. Long-term survival analysis of stereotactic ablative radiotherapy versus liver resection for small hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2017;98:639-46.

35. Parikh ND, Waljee AK, Singal AG. Downstaging hepatocellular carcinoma: a systematic review and pooled analysis. Liver Transpl 2015;21:1142-52.

36. Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology 2015;61:1968-77.

37. Yopp AC, Mansour JC, Beg MS, Arenas J, Trimmer C, et al. Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome. Ann Surg Oncol 2014;21:1287-95.

38. Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 1979;5:85-91.

39. Wahl DR, Stenmark MH, Tao Y, Pollom EL, Caoili EM, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol 2016;34:452-9.

40. Sapir E, Tao Y, Schipper MJ, Bazzi L, Novelli PM, et al. Stereotactic body radiation therapy as an alternative to transarterial chemoembolization for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2018;100:122-30.

41. Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 2013;31:1631-9.

42. Kang JK, Kim MS, Cho CK, Yang KM, Yoo HJ, et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer 2012;118:5424-31.

43. Scorsetti M, Comito T, Cozzi L, Clerici E, Tozzi A, et al. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). J Cancer Res Clin Oncol 2015;141:1301-9.

44. Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium (REBOC). Int J Radiat Oncol Biol Phys 2007;68:13-23.

45. Johnson DT, Kesner AL. Yttrium-90 selective internal radiation therapy. In: Meyer J, Schefter T, editors. Radiation Therapy for Liver Tumors. Germany: Springer, Cham; 2017.

46. Hilgard P, Hamami M, Fouly AE, Scherag A, Müller S, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: european experience on safety and long-term survival. Hepatology 2010;52:1741-9.

47. Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2016;151:1155-63.

48. Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 2011;54:868-78.

49. Menon KM, Khosla A, Trimmer CK. Principles of intra-arterial therapies. In: Meyer J, Schefter T, editors. Radiation Therapy for Liver Tumors. Germany: Springer, Cham; 2017.

50. Atassi B, Bangash AK, Lewandowski RJ, Ibrahim S, Kulik L, et al. Biliary sequelae following radioembolization with yttrium-90 microspheres. J Vasc Interv Radiol 2008;19:691-7.

51. Gil-Alzugaray B, Chopitea A, Iñarrairaegui M, Bilbao JI, Rodriguez-Fraile M, et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology 2013;57:1078-87.

52. Lasley FD, Mannina EM, Johnson CS, Perkins SM, Althouse S, et al. Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy. Pract Radiat Oncol 2015;5:e443-9.

53. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.

54. Hiraoka A, Kumada T, Kariyama K, Takaguchi K, Itobayashi E, et al. Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: multicenter analysis. Hepatol Res 2018; doi: 10.1111/hepr.13243.

55. Kang J, Demaria S, Formenti S. Current clinical trials testing the combination of immunotherapy with radiotherapy. J Immunother Cancer 2016;4:51.

56. Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui M, Garralda E, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013;59:81-8.

57. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.

58. Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for hepatocellular carcinoma. Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm625705.htm. [Last accessed on 7 Jan 2019].

59. Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018;19:940-52.

60. Haikerwal SJ, Hagekyriakou J, MacManus M, Martin OA, Haynes NM, et al. Building immunity to cancer with radiation therapy. Cancer Lett 2015;368:198-208.

61. Chen L, Narang A, Thompson E, Anders R, Waters K, et al. Characterizing tumor infiltrating lymphocytes following neoadjuvant chemotherapy and radiation in pancreatic adenocarcinoma. Int J Radiat Biol Phys 2017;99:S91-2.

62. Reese AS, Feigenberg SJ, Husain A, Webb TJ, Hausner PF, et al. Stereotactic ablative radiotherapy (SABR): impact on the immune system and potential for future therapeutic modulation. Mol Cell Pharmacol 2013;5:19-25.

63. Kim KJ, Kim JH, Lee SJ, Lee EJ, Shin EC, et al. Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model. Oncotarget 2017;8:41242-55.

64. Gustafson MP, Bornschlegl S, Park SS, Gastineau DA, Roberts LR, et al. Comprehensive assessment of circulating immune cell populations in response to stereotactic body radiation therapy in patients with liver cancer. Adv Radiat Oncol 2017;2:540-7.

65. Schefter TE, Kavanagh BD, Timmerman RD, Cardenes HR, Baron A, et al. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys 2005;62:1371-8.

66. Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 2010;76:S94-100.

67. Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, et al. Stereotactic body radiation therapy: the report of AAPM task group 101. Med Phys 2010;37:4078-101.

68. Cárdenes HR, Price TR, Perkins SM, Maluccio M, Kwo P, et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol 2010;12:218-25.

69. El Fouly A, Ertle J, El Dorry A, Shaker MK, Dechêne A, et al. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? Liver Int 2015;35:627-35.

70. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010;138:52-64.

Hepatoma Research
ISSN 2454-2520 (Online) 2394-5079 (Print)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/